Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy - A Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter Trial
Latest Information Update: 27 Nov 2025
At a glance
- Drugs Enavogliflozin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms EMPACT
Most Recent Events
- 27 Nov 2025 New trial record